Mutual of America Capital Management LLC Sells 5,110 Shares of Illumina, Inc. (NASDAQ:ILMN)

Mutual of America Capital Management LLC lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.6% during the third quarter, Holdings Channel reports. The firm owned 86,095 shares of the life sciences company’s stock after selling 5,110 shares during the period. Mutual of America Capital Management LLC’s holdings in Illumina were worth $11,228,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ILMN. Vanguard Group Inc. raised its position in Illumina by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock valued at $2,505,409,000 after buying an additional 66,528 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after purchasing an additional 204,043 shares during the last quarter. Capital World Investors lifted its position in shares of Illumina by 41.1% during the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock valued at $378,111,000 after purchasing an additional 801,814 shares in the last quarter. Primecap Management Co. CA boosted its holdings in Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after purchasing an additional 1,997,010 shares during the last quarter. Finally, GUARDCAP ASSET MANAGEMENT Ltd grew its position in Illumina by 1.1% in the 1st quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock worth $284,097,000 after purchasing an additional 22,067 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Daiwa Capital Markets upgraded Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $120.00 to $154.00 in a research note on Friday, August 16th. TD Cowen upped their price objective on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Leerink Partners lifted their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Citigroup lifted their price objective on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $164.00.

Illumina Price Performance

ILMN stock opened at $135.05 on Monday. The firm has a 50 day moving average of $139.66 and a 200-day moving average of $124.31. The firm has a market capitalization of $21.42 billion, a P/E ratio of -13.56 and a beta of 1.13. Illumina, Inc. has a 12 month low of $92.69 and a 12 month high of $156.66. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the previous year, the business earned $0.33 EPS. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.